Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis

BACKGROUND: In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief. OBJECTIVES: We examined clinically meaningful improvements in selected patient‐reported outcomes (PROs). METHODS: JADE COMPARE was a multicentre, phase 3 randomized, double‐blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Thyssen, J.P., Yosipovitch, G., Paul, C., Kwatra, S.G., Chu, C.‐Y., DiBonaventura, M., Feeney, C., Zhang, F., Myers, D., Rojo, R., Valdez, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Allergy and Eczema
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300205/
https://www.ncbi.nlm.nih.gov/pubmed/34779063
http://dx.doi.org/10.1111/jdv.17813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300205/
https://www.ncbi.nlm.nih.gov/pubmed/34779063
http://dx.doi.org/10.1111/jdv.17813

Ejemplares similares